Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer

Bartsch, Rupert; Wenzel, Catharina; Altorjai, Gabriela; Pluschnig, Ursula; Rudas, Margaretha; Mader, Robert M.; Gnant, Michael; Zielinski, Christoph; Steger, Guenther G.

doi:10.1200/jco.2007.11.9776

Cited by 139 publications

(77 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was associated with a clinical benefit rate of 70%. In addition, the time to progression (TTP) of 8 months and overall survival duration of 24 months were much higher than those seen in historical controls of patients treated with capecitabine monotherapy [3]. A retrospective analysis of 136 patients with HER-2/neu ϩ breast cancer found that 66 and 47 patients received trastuzumab in the first and second line, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…However, prior to the 2009 publication of a clinical trial showing a higher response rate and longer progression-free survival interval, there were no randomized data to support this practice. There were only data from uncontrolled studies [2,3] and case series [4 -7] suggesting that the practice was safe and not associated with excess toxicity. In addition, responses and longer survival were seen with subsequent lines of trastuzumabbased therapy; however, given the lack of randomization, several articles called for randomized trials to clarify the true benefit [8,9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?

et al. 2011

View full text Add to dashboard Cite

Background. The role of continued trastuzumab after progression in women with human epidermal growth factor receptor (HER)-2 ؉ metastatic breast cancer is controversial. Controlled clinical trials that establish a benefit from continued trastuzumab have been difficult to complete.Methods. In the National Comprehensive Cancer Center Network (NCCN) Breast Cancer Outcomes Database, we identified women treated with trastuzumab for metastatic or relapsed HER-2 ؉ breast cancer at eight NCCN centers who subsequently progressed. Patients were eligible for this analysis if they initiated treatment at an NCCN institution between July 1997 and December 2004, received trastuzumab-containing treatment, and progressed while on therapy. We calculated the proportion of patients who received trastuzumab after progression, and in a multivariate analysis assessed the association of pa-

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Moreover, phase II studies investigating the efficacy and tolerability of trastuzumab in combination with paclitaxel have shown diarrhoea to be the most frequent toxicity manifesting in 30 % of patients [87]. Toxicity profiling for newer combination regimens where trastuzumab is given with carboplatin or capecitabine has shown significant induction of mucositis, diarrhoea and vomiting at grade 3-4 intensity [88,89].…”

Section: Targeted Anti-cancer Agents and Mucosal Injurymentioning

confidence: 99%

Emerging evidence on the pathobiology of mucositis

Al‐Dasooqi

Sonis

Bowen

et al. 2013

Support Care Cancer

169

View full text Add to dashboard Cite

Background Considerable progress has been made in our understanding of the biological basis for cancer therapyinduced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely. Methods Panel members reviewed the biomedical literature on mucositis pathobiology published between January 2005 and December 2011.Results Recent research has provided data on the contribution of tissue structure changes, inflammation and microbiome changes to the development of mucositis. Additional research has focused on targeted therapyinduced toxicity, toxicity clustering and the investigation of genetic polymorphisms in toxicity prediction. This review paper summarizes the recent evidence on these aspects of mucositis pathobiology. Conclusion The ultimate goal of mucositis researchers is to identify the most appropriate targets for therapeutic interventions and to be able to predict toxicity risk and personalize interventions to genetically suitable patients. Continuing research efforts are needed to further our understanding of mucositis pathobiology and the pharmacogenomics of toxicity.

show abstract

“…On the other hand, changing the traditional treatment paradigm in patients progressing on trastuzumab and administering further trastuzumab-based therapy beyond disease progression may have clinical benefit [65][66].This "treatment beyond progression" approach is increasingly being studied in clinical trials by combining trastuzumab either with chemotherapy [67][68] or with another targeted agent, such as the RTKI lapatinib [69]. Trastuzumab-DM1 (T-DM1) is an anti-HER-2 antibody drug conjugate comprising trastuzumab linked to the maytansine derivative DM1.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%